STOCK TITAN
  1. Home
  2. News
  3. RNXT

RenovoRx, Inc. - RNXT STOCK NEWS

Welcome to our dedicated page for RenovoRx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.

RenovoRx, Inc. (RNXT) is a medical device and biopharmaceutical company based in Silicon Valley, California. The company focuses on developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents to specific locations in the peripheral vascular system. With FDA clearance for their flagship product, RenovoCath™ RC120, RenovoRx is introducing this cutting-edge technology to the clinical market.

RenovoRx's proprietary platform, Trans-Arterial Micro-Perfusion (TAMP), aims to revolutionize cancer treatment by ensuring precise therapeutic delivery directly to the tumor site. This targeted approach is designed to reduce the toxicities commonly associated with systemic intravenous therapy, potentially improving therapeutic outcomes for cancer patients.

The company is driven by a highly motivated team with extensive experience in the medical field and supported by a robust medical advisory board and a distinguished board of directors. RenovoRx's commitment to innovation and patient care has positioned it as a leader in the area of targeted therapeutic delivery.

For more information or inquiries, please contact RenovoRx at info@renovorx.com.

News

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

Rhea-AI Summary
RNXT - RenovoRx Announces Financial Results and Collaboration with Imugene for TAMP Platform Expansion. The company remains focused on advancing its Phase III TIGeR-PaC clinical trial for the treatment of LAPC. Collaboration with Imugene further validates the TAMP platform and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy. Financial results for the third quarter ended September 30, 2023, show a cash position of $3.2 million, increased R&D expenses, flat G&A expenses, a net loss of $1.4 million, and 10,693,080 outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.38%
Tags
earnings
-
News

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

Rhea-AI Summary
RenovoRx CEO Shaun Bagai to present at ROTH MKM Healthcare Opportunities Conference on October 12, 2023. Bagai will discuss recent milestones including research collaboration with Imugene and highlights from Phase III TIGeR-PaC study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.92%
Tags
conferences
-
News

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

Rhea-AI Summary
RenovoRx announces positive Phase III TIGeR-PaC interim study results, collaboration with Imugene, and financial results for Q2 2023. The study shows an 8-month delay in cancer progression, 6-month overall survival benefit, and 65% reduction in adverse effects. The collaboration aims to explore oncolytic virus therapy using RenovoRx's TAMP platform. Q2 financial results show $6.0 million in cash and cash equivalents, $1.9 million in R&D expenses, and $1.4 million in G&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
earnings
News

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
-
News

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
News

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

Rhea-AI Summary
RenovoRx presents positive data on RenovoGem in the treatment of locally advanced pancreatic cancer. The interim analysis shows an eight-month median progression-free survival benefit for patients receiving RenovoGem compared to standard-of-care. The study also demonstrates a 65% reduction in adverse events and a clinically meaningful overall survival trend. RenovoGem has the potential to change the treatment paradigm for pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
clinical trial
News

RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
management
-
News

RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
-
News

RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial

Rhea-AI Summary
RenovoRx, Inc. announced that the University of Texas Southwestern Medical Center is enrolling pancreatic cancer patients in a Phase III clinical trial. The study is investigating RenovoGem as a potential new treatment option for Locally Advanced Pancreatic Cancer (LAPC). Interim analysis data revealed a 60% survival benefit and a 65% reduction in side effects compared to standard of care treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.44%
Tags
clinical trial
News

RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none

FAQ

What is the current stock price of RenovoRx (RNXT)?

The current stock price of RenovoRx (RNXT) is $1.25 as of December 20, 2024.

What is the market cap of RenovoRx (RNXT)?

The market cap of RenovoRx (RNXT) is approximately 27.6M.

What does RenovoRx, Inc. specialize in?

RenovoRx specializes in developing targeted delivery solutions for fluids, including diagnostic and therapeutic agents, in the peripheral vascular system.

What is the RenovoCath™ RC120?

RenovoCath™ RC120 is a medical device developed by RenovoRx for targeted therapeutic delivery. It has received FDA clearance.

What is the Trans-Arterial Micro-Perfusion (TAMP) platform?

The TAMP platform is RenovoRx's patented technology designed for precise therapeutic delivery directly to tumor sites, potentially reducing toxicities associated with systemic therapies.

Where is RenovoRx headquartered?

RenovoRx is headquartered in Silicon Valley, California.

Who backs RenovoRx's initiatives?

RenovoRx is backed by a broad medical advisory board and a strong board of directors.

What is the primary goal of RenovoRx's therapies?

The primary goal is to improve therapeutic outcomes for cancer patients by directly targeting tumors and minimizing treatment toxicities.

How can I contact RenovoRx for more information?

You can contact RenovoRx via email at info@renovorx.com.

What makes RenovoRx's technology unique?

Their technology ensures high-concentration delivery of therapeutic agents to specific vasculature without perfusion overlap to other regions, enhancing treatment efficacy and safety.

Is RenovoRx currently in clinical stages?

Yes, RenovoRx is a clinical-stage biopharmaceutical company.

What recent achievements has RenovoRx made?

RenovoRx has received FDA clearance for RenovoCath™ RC120 and is actively introducing its innovative technology to the clinical market.

Stock RNXT logo
RenovoRx, Inc.

Nasdaq:RNXT

RNXT Rankings

#5163 Ranked by Market Cap
N/A Ranked by Dividends

RNXT Stock Data

27.60M
23.54M
1.9%
8.18%
0.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN JOSE